Pfizer’s CEO was among the more than 200 pharmaceutical company executives who signed the letter after a federal judge’s controversial ruling on mifepristone.
Dueling court rulings out of Washington state and Texas have created confusion about the abortion pill mifepristone’s legal status in the U.S.
Danco Laboratories will likely ask the Supreme Court to intervene if the 5th Circuit does not at least temporarily block Kacsmaryk’s decision.
A federal judge in Texas on Friday stayed the FDA’s appwroval of the abortion pill mifepristone, but delayed the ruling taking effect for a week, giving time to appeal.
Federal Judge Matthew Kacsmaryk raised the Comstock Act repeatedly in last week’s hearing for the case challenging FDA approval of mifepristone.
The judge could order the FDA to withdraw mifepristone. He could also stop short of blocking sales and impose tougher restrictions on distribution instead.
Federal Judge Matthew Kacsmaryk asked attorneys in a pivotal case over the abortion pill mifepristone to not disclose a key hearing set for Wednesday.
The lawsuit adds to an escalating series of legal battles over access to the abortion pill in the U.S.
The 22 attorneys general argued the attempt to pull the abortion pill from the U.S. market would have “devastating consequences” for women.
The abortion rights group NARAL Pro-Choice America, in an analysis published Friday, said 40 million women could lose access to the abortion pill.
The FDA is changing the informational packaging of the emergency contraceptive pill, Plan B One-Step, to clarify that it is not an abortion pill.
The CDC, in a report published Wednesday, found that about 51% of abortions in 2020 were performed with the pill at or before the ninth week of pregnancy.